Phase II Study of Metronomic Chemotherapy Using POLF Regimen in the Treatment of Advanced Gastric Cancer
Overview
- Phase
- Phase 2
- Intervention
- Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
- Conditions
- Metastatic Gastric Cancer
- Sponsor
- Huashan Hospital
- Enrollment
- 40
- Locations
- 2
- Primary Endpoint
- response rate
- Last Updated
- 9 years ago
Overview
Brief Summary
phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin, Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer
Detailed Description
About 80% of patients with advanced gastric cancer are diagnosed at an advanced stage with limited treatment options including systemic chemotherapy with or without radiation. Commonly used maximally tolerated dose (MTD) chemotherapy such as DCT, ECF, FOLFOX regimens induce responses in the range of 20 to 50% with median survival in the range of 10 to 12 months. Metronomic chemotherapy has been found to have more consistent anti-tumor effects through anti-angiogenic and immunomodulating effects. Preliminary clinical studies of weekly POLF have found very encouraging clinical activities and low overall toxicities in pancreatic cancer and gastric cancer. Here we conduct a formal clinical trial to determine the clinical efficacy and side effect profiles of this regimen in patients with advanced gastric cancer.
Investigators
Nick Chen
Visiting Professor
Huashan Hospital
Eligibility Criteria
Inclusion Criteria
- •pathologically confirmed gastric cancer AJCC stage III or IV
- •measurable disease based on CT or endoscopy exam
- •non-surgical candidates or patients who declined surgery
- •non-radiation candidates or patients who declined radiation
- •patients who are able to sign informed consent
- •patients who are 2 weeks out and recovered from surgery
- •patients who have completed radiation to relieve obstructive symptoms
- •patient who previously received Oxaliplatin and 5-FU in other MTD regimens
- •adequate marrow function: neutrophil \>1000/ul, Hgb \>10g/dl, Plt\>50,000
Exclusion Criteria
- •allergic to any of the drugs involved
- •concurrent malignancies
- •severe co-morbidities of heart, lungs, kidneys and bone marrow
- •severe psychological disorder
- •severe malnutrition
- •difficult to heal or unhealed wound
- •ECOG performance status equal or over 3
- •uncontrolled complications from the malignancy
- •uncontrolled CNS metastasis
- •peripheral neuropathy grade 3 or above
Arms & Interventions
POLF regimen
Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
Intervention: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
Outcomes
Primary Outcomes
response rate
Time Frame: 3 months
based on Recist 1.1
Secondary Outcomes
- progression free survival(2 years)
- overall survival(2 years)
- adverse events(2 years)